United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $24,712,246.04. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $547.69 on Friday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market capitalization of $23.25 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. The business’s fifty day moving average is $568.06 and its 200 day moving average is $518.61.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business posted $6.63 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at about $31,000. International Assets Investment Management LLC grew its stake in shares of United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.